Das maligne Mesotheliom der Pleura

Zusammenfassung

Das maligne Mesotheliom der Pleura (MMP) ist ein hoch aggressiver Tumor, welcher dem pleuralen Mesothel entstammt. Die Asbestexposition ist der wichtigste Faktor in der Pathogenese des MMP und entsprechend des erst späten Verbots dieser Substanz im Jahre 2005 wird der Gipfel der Neuerkrankungen in Europa für die nächsten zwanzig Jahre erwartet. Das stark aggressive Verhalten dieses Tumors zeigt sich in einer schlechten Prognose mit einem mittleren Überleben zwischen sieben und neun Monaten. Trotz aller Fortschritte, die in der Diagnostik und Therapie dieser Entität gemacht wurden, ist die optimale Behandlung immer noch Gegenstand der Diskussion. In diesem Artikel wird der aktuelle Stand der Diagnostik und Therapie diskutiert.

Abstract

Malignant pleural mesothelioma (MMP) is a highly aggressive tumor arising of the pleural mesothelium. Asbestos exposure is the main factor involved in the pathogenesis of MMP and according to the late ban of this agent in 2005 the peak incidence in Europe is expected in the next twenty years. The highly aggressive behaviour of this tumor results in a poor prognosis with a mean overall survival between 7 and 9 months. Despite the progress made in diagnosis and therapy of this entity the optimal treatment remains a subject of debate. In this article we review the current state of treatment and diagnosis.

Schlüsselwörter

intracavitäre hypertherme Chemotherapie - Asbest - multimodale Therapie - Mesotheliom

Keywords

intracavitary intraoperative hyperthermic chemotherapy - asbestos - multimodal treatment - mesothelioma

• Literatur

• 1 Alberts AS, Falkson G, Goedhals L et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527-535
• 2 Antony VB, Loddenkemper R, Astoul P et al. Management of malignant pleural effusions. Eur Respir J 2001; 18: 402-419
• 3 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Diagnostik und Begutachtung asbestbedingter Berufskrankheiten. http://www.awmf.org/uploads/tx_szleitlinien/002-038l_S2k-Diagnostik_und_Begutachtung_asbestbedingter_Berufskrankheiten_2010-12.pdf
• 4 Balduyck B, Trousse D, Nakas A et al. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?. Ann Thorac Surg 2010; 89: 907-911
• 5 Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol) 1991; 3: 315-317
• 6 Bogliolo GV, Lerza R, Bottino GB et al. Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 1991; 27: 839-842
• 7 Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-758
• 8 Branscheid D, Krysa S, Bauer E et al. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 1991; 5: 466-472
• 9 Cao CQ, Yan TD, Bannon PG et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010; 5: 1692-1703
• 10 Ceresoli GL, Locati LD, Ferreri AJ et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34: 279-287
• 11 Chi A, Liao Z, Nguyen NP et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 1132-1141
• 12 British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001; 56: 250-265
• 13 Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994; 38: 212-214
• 14 de Bree E, van Ruth S, Baas P et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480-487
• 15 Deutschen Gesetzlichen Unfallversicherung DGUV. http://www.dguv.de/inhalt/zahlen/bk/bestaetigte/index.jsp abgerufen am 05.09.2011
• 16 Elmes PC, Simpson JC. The clinical aspects of mesothelioma. Q J Med 1976; 45: 427-449
• 17 Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135: 620-626
• 18 Flores RM, Zakowski M, Venkatraman E et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007; 2: 957-965
• 19 Goldberg M, Imbernon E, Rolland P et al. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006; 63: 390-395
• 20 Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 1999; 56: 505-513
• 21 Husain AN, Colby TV, Ordonez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331
• 22 Iwatsubo Y, Pairon JC, Boutin C et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study. Am J Epidemiol 1998; 148: 133-142
• 23 Kent M, Rice D, Flores R. Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2008; 9: 158-170
• 24 Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34: 718-721
• 25 Lerza R, Esposito M, Vannozzi M et al. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses. Cancer 1994; 73: 79-84
• 26 Leslie H, Sobin MKG, Wittekind C Hrsg. TNM Classification of Malignant Tumours (UICC International Union Against Cancer). 7th. Edition. Aufl; 2009
• 27 Low EM, Khoury GG, Matthews AW et al. Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy. Clin Oncol (R Coll Radiol) 1995; 7: 317-318
• 28 Merritt N, Blewett CJ, Miller JD et al. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 2001; 78: 171-174
• 29 Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694
• 30 Neumann V, Gunthe S, Mulle KM et al. Malignant mesothelioma--German mesothelioma register 1987-1999. Int Arch Occup Environ Health 2001; 74: 383-395
• 31 Neumann V, Rutten A, Scharmach M et al. Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register. Int Arch Occup Environ Health 2004; 77: 191-199
• 32 O'Rourke N, Garcia JC, Paul J et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22
• 33 Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-672
• 34 Pilling JE, Stewart DJ, Martin-Ucar AE et al. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2004; 25: 497-501
• 35 Ribak J, Lilis R, Suzuki Y et al. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death. Br J Ind Med 1988; 45: 182-187
• 36 Richards WG, Zellos L, Bueno R et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24: 1561-1567
• 37 Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157-1168
• 38 Rusch VW, Rosenzweig K, Venkatraman E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788-795
• 39 Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495
• 40 Schipper PH, Nichols FC, Thomse KM et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008; 85: 257-264
• 41 Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63
• 42 Takagi K, Tsuchiya R, Watanabe Y. Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 2001; 31: 57-65
• 43 Tilleman TR, Richards WG, Zellos L et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009; 138: 405-411
• 44 Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004; 45 (Suppl. 01) 103-119
• 45 van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889
• 46 Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644
• 47 Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-271
• 48 Weder W, Opitz I, Stahel R. Multimodality strategies in malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009; 21: 172-176
• 49 Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008; 9: 147-157